Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
2.2 Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC
2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine
2.5 What Do the Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers
4.2 Classification or Staging Systems

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods, Population
5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer
5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category
5.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis
5.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
5.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status
5.5 Epidemiological Forecast for Prostate Cancer (2018-2028)
5.5.1 Diagnosed Incident Cases of Prostate Cancer
5.5.2 Age-Specific Incident Cases of Prostate Cancer
5.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score
5.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category
5.5.6 Metastatic Cases at Diagnosis
5.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer
5.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6.1 Diagnosis and Treatment Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 France
6.5 Germany
6.6 Italy
6.7 Spain
6.8 UK
6.9 Japan
6.10 China

7.1 Overview

8.1 Overview
8.2 Therapies with a Durable OS Benefit or Cure for mCRPC
8.3 Identification of New Targets and Positive Predictive Biomarkers of Response
8.4 Advancements in the Detection and Treatment of Drug Resistance
8.5 Therapeutic Options for nmCRPC

9.1 Overview
9.2 Promising Drugs in Clinical Development

10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Johnson & Johnson
10.3.2 Astellas
10.3.3 AstraZeneca
10.3.4 Bayer
10.3.5 Clovis Oncology
10.3.6 Merck
10.3.7 Novartis
10.3.8 Pfizer
10.3.9 Roche
10.3.10 Sanofi

11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China (Urban)
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

Table 1: Prostate Cancer: Key Metrics in Eight Major Pharmaceutical Markets
Table 2: Stage Definitions for PCa
Table 3: NCCN Risk-Category Classification System for PCa
Table 4: Risk Factors and Comorbidities for Prostate Cancer
Table 5: AJCC Staging of Prostate Cancer
Table 6: Treatment Guidelines for Prostate Cancer
Table 7: Country Profile - US
Table 8: Country Profile - France
Table 9: Country Profile - Germany
Table 10: Country Profile - Italy
Table 11: Country Profile - Spain
Table 12: Country Profile - UK
Table 13: Country Profile - Japan
Table 14: Country Profile - China
Table 15: Leading Branded Treatment for PCa, 2019
Table 16: Key Companies in the PCa Market in the 8MM, 2018-2028
Table 17: J&J’s PCa Portfolio Assessment, 2019
Table 18: Astellas’ PCa Portfolio Assessment, 2019
Table 19: AstraZeneca’s PCa Portfolio Assessment, 2019
Table 20: Bayer’s PCa Portfolio Assessment, 2019
Table 21: Clovis Oncology’s PCa Portfolio Assessment, 2019
Table 22: Merck’s PCa Portfolio Assessment, 2019
Table 23: Novartis’ PCa Portfolio Assessment, 2019
Table 24: Pfizer’s PCa Portfolio Assessment, 2019
Table 25: Roche’s PCa Portfolio Assessment, 2019
Table 26: Sanofi’s PCa Portfolio Assessment, 2019
Table 27: Prostate Cancer Market - Global Drivers and Barriers, 2018-2028
Table 28: Key Events Impacting Sales for Prostate Cancer in the US, 2018-2028
Table 29: Prostate Cancer Market -Drivers and Barriers in the US, 2018-2028
Table 30: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2018-2028
Table 31: Prostate Cancer Market - Drivers and Barriers in the 5EU, 2018-2028
Table 32: Prostate Cancer Market in the 5EU - Country-Specific Barriers in the 5EU, 2018-2028
Table 33: Key Events Impacting Sales for Prostate Cancer in Japan, 2018-2028
Table 34: Prostate Cancer Market - Drivers and Barriers in Japan, 2018-2028
Table 35: Key Events Impacting Sales for Prostate Cancer in China, 2018-2028
Table 36: Prostate Cancer Market - Drivers and Barriers in China, 2018-2028
Table 37: Key Historical and Projected Launch Dates for Prostate Cancer
Table 38: Key Projected Patent Expiry/Market Exclusivity Dates for Prostate Cancer
Table 39: Average Body BSA Across the 8MM
Table 40: High-Prescribing Physicians (non-KOLs) Surveyed, by Country and Specialty

Figure 1: Global Sales Forecast by Country for Prostate Cancer in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Prostate Cancer During the Forecast Period, 2018-2028
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Prostate Cancer, 2018-2028
Figure 4: 8MM, Diagnosed Incidence of Prostate Cancer, Men, Ages =30 Years, 2008-2028
Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer
Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Risk Category
Figure 9: 8MM, Sources Used, Metastatic Cases at Diagnosis
Figure 10: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
Figure 11: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC
Figure 12: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC by Status
Figure 13: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages =30 Years, Men, N, 2018
Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, N, 2018
Figure 15: 8MM, Diagnosed Incident Cases of Prostate Cancer by Gleason Score, Ages =30 Years, Men, N, 2018
Figure 16: 8MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Ages =30 Years, Men, N, 2018
Figure 17: 8MM, Diagnosed Incident Cases of Prostate Cancer by Risk Category, Ages =30 Years, Men, N, 2018
Figure 18: 8MM, Metastatic Cases at Diagnosis, Ages =30 Years, Men, N, 2018
Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages =30 Years, Men, N, 2018
Figure 20: 8MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status, Ages =30 Years, Men, N, 2018
Figure 21: Treatment Algorithm for Localized Prostate Cancer
Figure 22: Treatment Algorithm for Progressive and Advanced Prostate Cancer
Figure 23: Overview of the Unmet Need and Opportunity in Prostate Cancer, 2019
Figure 24: Overview of the Development Pipeline in PCa
Figure 25: Pivotal Phase II/III Trials for the Promising PCa Pipeline Agents
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of PCa During the Forecast Period
Figure 27: Analysis of the Company Portfolio Gap in PCa During the Forecast Period
Figure 28: Global (8MM) Sales Forecast by Country for Prostate Cancer in 2018 and 2028
Figure 29: Global (8MM) Sales Forecast by Drug Class for Prostate Cancer in 2018 and 2028
Figure 30: Sales Forecast by Class for Prostate Cancer in the US in 2018 and 2028
Figure 31: Sales Forecast by Class for Prostate Cancer in the 5EU in 2018 and 2028
Figure 32: Sales Forecast by Class for Prostate Cancer in Japan in 2018 and 2028
Figure 33: Sales Forecast by Class for Prostate Cancer in China in 2018 and 2028